Where is Health Technology Assessment Going?
Add bookmark
Where is Health Technology Assessment Going?
Add bookmarkChrissie Fletcher, Director and Head of International Biostatistics at Amgen, talks to Helen Winsor from Pharma IQ, about innovation in clinical design, analysis and reporting. Fletcher discusses how she sees health economists and statisticians interacting going forwards, why there is so much emphasis on reporting for reimbursement and whether she expects pharma companies will try and do this more in-house, in the future. Fletcher also offers her thoughts on health economists who do not have a statistical background, how she sees the HTA evolving and its place in the next 5-10 years.
[inlinead]
Tags:
Chrissie Fletcher
HTA
Health Technology Assessment
clinical design
clinical analysis
clinical reporting
clinical evaluation
cost effectiveness
reimbursement
health economics
